Prelude Capital Management’s Gilead Sciences GILD Stock Holding History

Prelude Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-16,300	Closed	-$1.06M	–	1634
2019 Q4	$1.06M	Buy	+16,300	New	+$1.06M	0.04%	370
2019 Q3	–	Sell	-40,000	Closed	-$2.7M	–	1825
2019 Q2	$2.7M	Sell	40,000 -10,000	-20%	-$658K	0.13%	128
2019 Q1	$3.25M	Buy	50,000 +10,000	+25%	+$665K	0.18%	99
2018 Q4	$2.5M	Buy	+40,000	New	+$2.8M	0.17%	131
2018 Q3	–	Sell	-35,000	Closed	-$2.48M	–	1833
2018 Q2	$2.48M	Buy	+35,000	New	+$2.47M	0.16%	115

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prelude Capital Management's GILD Position: Q2 2026 in Review

Prelude Capital Management increased its Gilead Sciences (GILD) stake by 163% in Q2 2026, buying an estimated $382K and bringing the position to 4,684 shares worth $592K. The position accounts for 0.04% of the portfolio, ranked #463.

Prelude Capital Management first reported a position in GILD in Q2 2013 and has held it in 39 quarters since. The position peaked at $3.91M in Q4 2015. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Prelude Capital Management held 4,684 shares of Gilead Sciences worth $592K as of Q2 2026.
Prelude Capital Management bought 2,901 Gilead Sciences shares in Q2 2026, an estimated $382K.
Gilead Sciences made up 0.04% of Prelude Capital Management's portfolio in Q2 2026, its #463 holding.
Prelude Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 39 quarters since.
Prelude Capital Management's Gilead Sciences position peaked at $3.91M in Q4 2015.
2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.